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Large-scale cancer genomics efforts are identifying hun-
dreds of somatic genomic alterations in glioblastoma
(GBM). Distinguishing between active driver and neutral
passenger alterations requires functional assessment of
each gene; therefore, integrating biological weight of
evidencewithstatisticalsigniﬁcanceforeachgenomicalter-
ation will enable better prioritization for downstream
studies. Here, we demonstrate the feasibility and potential
ofinvitrofunctionalgenomicscreenstorapidlyandsystem-
atically prioritize high-probability candidate genes for in
vivo validation. Integration of low-complexity gain- and
loss-of-function screens designed on the basis of genomic
data identiﬁed 6 candidate GBM oncogenes, and RINT1
was validated as a novel GBM oncogene based on its
abilitytoconfertumorigenicitytoprimarynontransformed
murine astrocytes in vivo. Cancer genomics-guided low-
complexity genomic screens can quickly provide a func-
tional ﬁlter to prioritize high-value targets for further
downstream mechanistic and translational studies.
Keywords: functional genomics, glioblastoma,
oncogene, oncogenomics.
G
lioblastoma (GBM) is the most common and ag-
gressive primary brain tumor, and median sur-
vival is a mere 14 months from diagnosis.
1,2
GBMs are highly resistant to chemotherapeutics, and
surgical resection provides only temporary relief prior
to inevitable recurrence. Beyond well-known signature
genetic alterations in the phosphatidylinositol 3-kinase
(PI3K) and epidermal growth factor receptor (EGFR)
signaling pathways,
3,4 genomic characterization of the
GBM oncogenome has revealed signiﬁcant heterogenei-
ty in the proﬁles of genetic alterations harbored by any
single tumor.
4 Although few novel mutations are
highly recurrent in GBM, hundreds of low-frequency
events have been identiﬁed,
4 some of which likely
represent true cancer drivers.
5,6 Therefore, in addition
to statistical signiﬁcance, experimental demonstration
of cancer-relevant functions is required to prove the bio-
logical importance of these genomic candidates.
The challenge of functionally validating the large
number of candidate oncogenes identiﬁed via cancer
genomics efforts necessitates the use of genetic screening
platformsthatofferahigh-throughputmeansofsystemati-
cally assaying the functions of hundreds, even thousands,
of genes simultaneously. Historically, genetic screens
using cDNA or shRNA libraries have been effectively le-
veraged in the discovery of many known cancer genes.
Here, we used cancer genomic data from primary GBM
specimens to design focused cDNA and shRNA libraries
for use in gain- and loss-of-function screens. The integra-
tion of cancer genomics data with these functional geno-
mics approaches led to the identiﬁcation of RINT1 as a
novel ampliﬁed and transforming GBM oncogene.
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Anchorage-Independent Growth
All cell lines were maintained in DMEM or RPMI
(Invitrogen) supplemented with 10% fetal bovine serum
(FBS; Cell Generation) and 1% penicillin/streptomycin
unless otherwise noted. For 96-well anchorage-
independent growth screens, expression constructs
were arrayed and transfected into 293T cells in 96-well
plates. Viral supernatants were collected and used to
infect LN215 and LNZ308 cells in 96-well plates in the
presence of 8 mg/mL polybrene (Millipore). Mean cell
number per well was determined, and the infected
LN215 and LNZ308 cells were then seeded in 96-well
soft agar assays. Soft agar plates were monitored for 4
weeks for the appearance of colonies. Because of the
low background of these cell lines in this assay, all wells
containing colonies .10 cells were considered to be pos-
itive. All other soft agar assays were performed in tripli-
cate in 6-well plates with 10000 cells seeded per well in
regular medium containing 0.4% low-melting agarose
on bottom agar containing 0.7% low-melting agarose in
regular medium. After 2 weeks, these plates were
stained with Iodonitrotetrazolium Chloride (Sigma), and
the colonies were manually counted.
Arrayed shRNA Screens
The RNAi Consortium (TRC) at the Broad Institute gen-
erated a library of 473 pLKO.1 lentivirally delivered
shRNAs targeting 85 genes recurrently ampliﬁed in
GBM (Supplementary material, Table S4).
7 Viral super-
natants for individual shRNA constructs were then
produced in 293T cells in 96-well format and used to
infect LN215, LN229, LNZ308, and LN382 human
glioma cells in quadruplicate 384-well plates. The day
after infection, 2 replicate plates were selected with
puromycin to measure infection efﬁciency, and 5 days
after selection, all plates were assayed for relative cell
number using a luminometricassay in whichluminescence
is directly proportional to cell number (CellTiterGlo;
Promega). To rank gene hits, the screen results were
analyzed on a per-gene basis, and the effects of individ-
ual genes were compared between cell lines with and
without the given ampliﬁcation, using methodology pre-
viously used to identify TBK1 as synthetically lethal
with mutant KRAS.
8 In brief, the relative cell number
of each shRNA construct in each cell line was ﬁrst nor-
malized using the median and maximum absolute devia-
tion of a collection of 89 control shRNA constructs in
the same cell line. The shRNAs were next mapped
across cell lines and ranked according to the magnitude
of their differential cell proliferation score (i.e., the diffe-
rence of their means in each phenotype: with the gene
ampliﬁed vs. control). After the shRNAs were ranked
using this approach, an enrichment score was computed
for each gene based on the distribution of its shRNAs in
the list. This enrichment score was computed using a
2-sample statistic based on the likelihood ratio
9 and is
representative of both the extremeness of the differential
cell proliferation scores of shRNAs targeting a given
gene and of their consistency. The lower the shRNAs
of a given gene appeared in the list, the higher their (neg-
ative) enrichment score and the greater the decrease
in relative cell number that knockdown of the gene
produced between cell lines with and without the ampli-
ﬁcation. To account for the fact that different genes are
targeted by different numbers of shRNAs in the library,
we normalized each enrichment score with the use of
random permutations of an shRNA set of the same size.
This permutation test also provided nominal P values
for reach gene enrichment score. The end result is a list
of genes sorted by their normalized enrichment scores
and false discovery rate.
Proliferation Assay
To assay growth after RINT1 knockdown, 1000 cells
per well were seeded into 96-well plates. The next day,
cell seeding was assessed using CellTiterGlo, and exper-
imental cells were infected with lentiviral shRNA con-
structs. Infected cells received fresh medium 24 h after
infection and, 24 h later, were switched to media with
or without puromycin; viability was scored 6 days later.
Tumorigenicity Studies
For in vivo tumorigenicity assays, 10
6 cells were mixed
with 50% matrigel (Fisher), transplanted subcutaneous-
ly into ﬂanks of Ncr nude mice (Taconic), and observed
for tumor development. Each subline was injected bilat-
erally in 5 mice, and time to tumor development was
monitored for each injection site. Tumor development
was deﬁned as the point at which tumor volume exceed-
ed a minimum of 20 mm
3, as determined by the equation
l. w. h.p/6( l ¼ length, w ¼ width, h ¼ height). In
cases in which an animal was euthanized prior to
tumor development, any tumor-free injection sites
were censored from the analysis. All animal experiments
were approved by Harvard’s Institutional Animal Care
and Use Committee under Protocol No. 04-136.
Plasmids
Open reading frames of 78 recurrently ampliﬁed genes
were obtained from the Human ORFeome Collection
and Open Biosystems. The Gateway recombination
system was used to transfer these cDNAs into the
pLenti6/V5-DEST (Invitrogen), pLenti6.3/V5-DEST,
and pBabe-puro-Gateway-HA expression vectors. For
the loss of function screens, we used constructs targeting
ampliﬁed genes from the TRC shRNA library.
7
Lentiviruses and retroviruses were produced in 293T
cells, and target cells were infected at 48 h and 72 h
after transfection in the presence of 8 mg/mL polybrene.
Infected cells were selected with 2 mg/mL puromycin for
3–5 days or 2.5–5 mg/mL blasticidin (Invitrogen) for
6 days before assaying expression. Lentivirally delivered
shRNA constructs targeting GFP and RINT1 were
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Web site (www.broadinstitute.org/trc).
Genomic Analyses
The sample setused foraCGHwaspreviouslydescribed
3
but included specimens from 28 pathologically veriﬁed
stage IV gliomas and 18 established human GBM cell
lines. The criteria for inclusion in the minimal common
region analysis required an amplicon to be present in at
least 2 samples (at least 1 of which was a tumor), be less
than 2 Mb in size, and to have a mean log2 amplitude
.1. A total of 20 recurrent amplicons containing 112
known and predicted genes met these criteria.
Validationofcopynumberampliﬁcationswasperformed
usingdatageneratedbyTCGAfromprimaryGBMspeci-
mens (July 28, 2011 Firehose run of the Broad Genome
Data Analysis Center [http://gdac.broadinstitute.org])
and from primary low-grade glioma specimens
(February 17, 2012 Firehose run of the Broad Genome
Data Analysis Center). Genes with copy number log2
ratio values .0.3 were designated to be in regions of
copy number gain. The Pearson correlation coefﬁcient
was used to assess the association of copy number
gain and the corresponding mRNA expression, and
the statistical signiﬁcance was evaluated using the
t statistic: tn−2 = r
 
n − 2/1 − r2

(r ¼ Pearson correla-
tion, n ¼ number of samples).
Immunohistochemistry and Immunoblot Analyses
Normal adult brain and primary GBM specimens were
preserved in 4% paraformaldehyde and embedded in
Optimum Cutting Temperature medium prior to sec-
tioning. Antigen retrieval was performed in Citrate
with steaming, and the specimens were probed with
anti-RINT1 antibody (Sigma). Visualization was per-
formed using the EnVision+ (DAB) detection system
(Dako, Carpenteria), and the specimens were counter-
stained with hematoxylin. For immunoblot analyses,
whole cell extracts were resolved using 4%–12%
Bis-Tris gradient gels (Invitrogen) and transferred to
PVDF membrane (Millipore) before being probed with
antibodies targeting RINT1 or Vinculin (H-10, Santa
Cruz Biotechnologies).
Statistical Analyses
Differences in tumor-free survival were assessed using
the log rank test in GraphPad Prism software.
Frequency of co-ampliﬁcation of genomic loci was
assessed using Fisher’s exact test with a maximum false
discovery rate of 5%. All other statistical differences
were assessed using 2-tailed, unpaired t tests.
Results and Discussion
Whole genome copy number analysis by array-based
CGH (aCGH) previously identiﬁed recurrent alterations
in the tumor genomes of patients with GBM.
3 Although
many known GBM-relevant oncogenes and tumor sup-
pressors were identiﬁed using this approach, a number
of these statistically signiﬁcant recurrently altered
regions did not contain known cancer-relevant genes.
On the basis of our dataset of 28 primary GBM speci-
mens and 18 human GBM cell lines,
3 we performed a
minimal common region (MCR) analysis to deﬁne 20
regions of recurrent ampliﬁcation containing a total of
112 known and predicted genes (Supplementary materi-
al, Table S1).
To determine the functional relevance of the candi-
date oncogenes residentin these regionsof ampliﬁcation,
we constructed cDNA and shRNA libraries to interro-
gate the biological activities of all genes for which
reagents were available. To identify candidate onco-
genes capable of driving transformation, open reading
frames (ORFs) representing 78 of the 112 ampliﬁed
genes were cloned into a lentiviral expression plasmid
(Supplementary material, Table S2). We then performed
an arrayed gain-of-function screen in 96-well format to
identify ORFs capable of promoting anchorage-indepen-
dent growth in soft agar in 2 human GBM cell lines
(LN215 and LNZ308) chosen for their low background
activity in this assay. Both LN215 and LNZ308 are wild
type for CDKN2A and mutant for TP53; LNZ308 cells
are also mutant for PTEN, and LN215 cells are wild
type at this locus.
10 Visual scoring of colonies with
.10 cells in this primary screen identiﬁed 17 ORFs
capable of conferring anchorage-independent growth
in at least one of these cell lines (Supplementary materi-
al, Table S3).
In parallel, hypothesizing that driver alterations lead
to oncogeneaddiction inestablished cancercells, weper-
formed an arrayed RNAi loss-of-function screen in 4
human GBM cell lines chosen for their representative
genetic backgrounds: LN215, LN229, LN382, and
LNZ308. All 4 lines carry mutations in TP53, but in
contrast to LN215 and LNZ308, LN229 and LN382
cells are both null for CDKN2A; LN229 cells are wild
type for PTEN, and LN382 cells carry a truncating
point mutation in PTEN.
10 A library of 473 lentivirally
delivered shRNA vectors targeting 85 of the ampliﬁed
genes (median of 5 shRNAs per gene; Supplementary
material, Table S4) was used to transduce individual
shRNAs in an arrayed fashion, and any shRNA reducing
relative proliferation by .1.5 standard deviations below
the mean of the control shRNAs was considered to be a
hit. Using this approach, 25 genes were identiﬁed as
either the top scorers in the cell lines that harbored
ampliﬁcations of the candidate gene or were the stron-
gest scoring genes of their amplicon across all cell lines
screened (Supplementary material, Table S5).
By combining the results of these gain-of-function
and loss-of-function screens, we identiﬁed 6 candidate
oncogenes (DYNC1I1, GLYCTK, NUP155, PLAGL2,
RINT1,a n dTWF2) that were both capable of promoting
anchorage-independent growth and required for the via-
bility and/or proliferation of GBM cancer cell lines
(Fig.1A).Theveracityofthisprioritizedlistwassupported
byourrecentworkdemonstratingthatPLAGL2isindeed
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presses differentiation of precursor cells, in part, through
activation of Wnt/b-catenin signaling.
11
As a ﬁrst step in validation, we sought to conﬁrm the
human relevance of these 6 prioritized candidates in a
larger cohort of human GBM samples. Speciﬁcally, we
leveraged the dataset generated by The Cancer
Genome Atlas on .480 primary GBM tumors for
which there were both copy number and mRNA expres-
sion data (July 28, 2011 Firehose run of the Broad
GDAC [http://gdac.broadinstitute.org]). On the basis
of the rationale that ampliﬁcation of a true oncogenic
driver would be expected to result in a concomitant
increase in mRNA expression level, we calculated the
correlation of copy number to mRNA expression level
across 484 primary GBM specimens characterized by
the TCGA (Fig. 1B). RINT1 demonstrated the highest
degree of copy number–correlated overexpression in
this dataset. Furthermore, the RINT1 locus (located on
7q22) exhibited copy number gains in 68% of patients
(log2 . 0.3; 343 of 501 samples) in the TCGA GBM
dataset, and 15.4% of patients (77 of 501 samples) ex-
hibited copy number gains greater than would be expect-
ed from trisomy in a homogeneous tumor cell
population (log2 . 0.6). Furthermore, in a recent cross-
tumor analysis of copy number alterations in .3100
tumor specimens,
12 RINT1 was found to be signiﬁcantly
ampliﬁed (q ¼ 0.13), strongly suggesting that RINT1 is
recurrently targeted for ampliﬁcation in human
tumors. Furthermore, as a complementary test of GBM
tumor relevance, we performed immunohistochemical
staining of RINT1 in specimens of normal adult brain
and primary GBM tumors (Fig. 1C). Although RINT1
expression was only observed in reactive astrocytes of
the cortex and subcortical white matter of normal
brain, primary GBM specimens exhibited a range of
RINT1 expression levels in the majority of tumor cells,
thus conﬁrming that RINT1 is expressed in primary
GBM tumors. Taken together, these data supported
the prioritization of RINT1 for functional validation
in vitro and in vivo.
To verify and extend the primary screen results, we
next conﬁrmed that RINT1 overexpression promoted
anchorage-independent growth in 3 independent GBM
cell lines, LNZ308, Hs683, and U343 cells (Fig. 2A).
Complementing these gain-of-function in vitro studies,
we also validated the requirement of RINT1 in main-
taining viability of established human GBM cells.
Here, 3 independent shRNAs targeting RINT1 used in
the primary screen were obtained, and relative suppres-
sion by each shRNA was assessed in LN340 cells by
immunoblot (Fig. 2B left panel). The 2 shRNAs with
Fig. 1. Integration of low-complexity genetic screens identiﬁed candidate GBM oncogenes. (A) Venn diagram summarizing the results of
independent primary genetic screens. Six genes were found to promote anchorage-independent growth and to be required for the
proliferation of human GBM cell lines. (B) Summary of copy number changes and correlation to mRNA expression data for the 6
candidates in 484 primary GBM specimens. RINT1 was amongst the most frequently targeted for copy number gain (log2 . 0.3) and
exhibited the greatest degree of copy number-correlated overexpression. (C) RINT1 is expressed in astrocytes and glioblastoma. (a)
Immunohistochemical staining for RINT1 in normal adult human brain shows strong expression in reactive astrocytes in the cortex and
subcortical white matter (brown stain), while staining in human GBM tumors shows a range of expression from strong diffuse
cytoplasmic (b) to low cytoplasmic levels in a smaller percentage of cells (c).
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p16
Ink4A/Arf2/2;Pten
2/2 primary nontransformed murine astrocytes were transduced with GFP, RINT1,o rPLAGL2 and injected
subcutaneously in nude mice. Overexpression of either RINT1 or PLAGL2 signiﬁcantly promoted tumor formation (P ¼ .002 and
P , .0001, respectively). (B) p16
Ink4A/Arf2/2 primary murine astrocytes were transduced with GFP or RINT1 and injected subcutaneously
in nude mice. RINT1 signiﬁcantly promoted tumor formation in these cells (P ¼ .002). Each experiment was performed at least twice,
and a representative experiment is shown. Representative photomicrographs (10× magniﬁcation) of hematoxylin and eosin–stained
sections of GFP- and RINT1-overexpressing tumors are included in the lower panels.
Fig. 2. Expression of RINT1 promotes anchorage-independent growth and is required for the viability of human GBM cell lines. (A)
Overexpression of RINT1 promoted soft agar colony formation in three human GBM cell lines. Each experiment was performed in
triplicate and repeated at least twice, and a representative experiment is shown. (B) Left panel: Three unique shRNAs targeting RINT1
were assessed for their ability to down-regulate RINT1 protein expression in LN340 cells relative to uninfected cells (Parental) or cells
infected with a nontargeting shRNA (shNTC) or an shRNA targeting GFP (shGFP). Right panel: The two shRNAs exhibiting the greatest
effect on RINT1 protein expression (sh234 and sh1052) were infected in a panel of human GBM cell lines and the relative viability of
each line was determined 7 days later using an ATP-based luminescence assay. The mean relative viability (+SD) of triplicate wells of
each cell line is plotted. The experiment shown is representative of triplicate experiments. *P , .05, **P , .005.
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which signiﬁcantly decreased RINT1 protein levels,
were then assessed for their impact on proliferation
and viability in a panel of 5 GBM cell lines, including
the 4 cell lines tested in the original loss-of-function
screen. These cell lines were selected for their range of
RINT1 copy number and expression status: LN340,
LN382, and LNZ308 exhibit copy number gains of
RINT1 (log2 . 0.3), whereas LN229 and GB1 do not
have ampliﬁcation of this locus but maintain expression
of RINT1 protein (Supplementary material, Fig. S1). As
shown in Fig. 2B, the viability of all 5 tested GBM cell
lines, independent of RINT1 copy number, was signiﬁ-
cantly reduced by at least 1 of the shRNAs targeting
RINT1. Examination of these cells conﬁrmed that intro-
duction of shRNAs that decrease RINT1 protein levels
signiﬁcantly decreased the growth of these cells,
whereas shRNAs that do not affect RINT1 protein
levels have no effect on growth.
Mindful of the limitations of in vitro assays in
established human GBM cells, we next tested the sufﬁ-
ciency of RINT1 to promote in vivo tumorigenesis in
primary nontransformed astrocytes isolated from geneti-
cally engineered mouse models. Speciﬁcally, we overex-
pressed RINT1 in primary immortalized murine
p16
Ink4a/Arf2/2; Pten
2/2 (Fig. 3A) and p16
Ink4a/Arf2/2
(Fig. 3B) astrocytes prior to subcutaneous transplanta-
tion in immunodeﬁcient mice. Overexpression of GFP
didnotsigniﬁcantlyaltertumorlatencyorpenetrancerel-
ativetoparentalastrocytes,andPLAGL2servedasapos-
itive control.
11 As shown in Fig. 3A, both PLAGL2- and
RINT1-overexpressing p16
Ink4a/Arf2/2; Pten
2/2 astro-
cytes formed subcutaneous tumors with signiﬁcantly
shorter latencyand higher penetrance than was observed
foreithertheparentalastrocytesaloneorastrocytesover-
expressing GFP (P ¼ .002 for RINT1 vs GFP; P , .0001
for PLAGL2 vs GFP). Overexpression of RINT1 also
signiﬁcantly promoted tumor formation (P ¼ .002) in
p16
Ink4a/Arf2/2 astrocytes (Fig. 3B), indicating that loss
of Pten was not required for RINT1 to promote tumori-
genesis. Taken together, these gain-of-function and
loss-of-function assays in both mouse and human cell
systems in vitro and in vivo validated RINT1 as a novel
GBM oncogene that is capable of transforming primary
murine astrocytes and is required for viability of estab-
lished human GBM cells.
To better understand the genetic context in which
RINT1 gain occurs, we assessed the frequency of
RINT1 alterations among tumors of the 4 transcriptomal
subtypes previously deﬁned by TCGA.
13 Overexpression
and copy number gain of RINT1 is observed signiﬁcantly
more frequently in classical-type tumors from the TCGA
sample set, although the degree of overrepresentation of
RINT1 alterations was less than that observed for
EGFR (Supplementary Material, Fig. S2). Although stat-
isticallysigniﬁcant,it is unlikely that this degreeof enrich-
ment of RINT1 alterations is sufﬁcient to drive the
mRNA expression proﬁle that deﬁnes classical-type
tumors. Furthermore, among the signature GBM genetic
alterations, ampliﬁcation of EGFR (P ¼ 1.28 × 10
216)
or MET (P ¼ 1.06 × 10
265) signiﬁcantly correlated
withincreasedRINT1copynumber.Althoughthisobser-
vation does not prove that these oncogenic receptor tyro-
sine kinases functionally cooperate with RINT1 in
primary tumors, the possibility of functional interaction
should be explored in future studies.
Advances in high-resolution microarrays and mas-
sively parallel sequencing have made it possible to char-
acterize cancer genomes and their evolution at an
unprecedented level.
4,14,15 To translate such genomic
discoveries into tangible therapeutic and diagnostic
end points in the clinic, extensive and time-consuming
functional studies are required to differentiate driver
from passenger mutations. Here, we have demonstrated
the feasibility of using low-complexity screens to rapidly
apply a biological ﬁlter to a set of candidate oncogenes
deﬁned by evidence of genomic copy number gains
and, through this approach, identiﬁed RINT1 as a
novel GBM oncogene.
RINT1 (or RAD50 interactor 1), as its name suggests,
was identiﬁed from a yeast-2-hybrid experiment to ﬁnd
proteins interacting with RAD50.
16 It has since been
shown to play complex roles in the G2/M checkpoint,
telomere elongation, maintenance of centrosome integri-
ty, and vesicle trafﬁcking between the endoplasmic retic-
ulum and Golgi apparatus.
16–19 Although some of these
studies have suggested a role as a tumor suppressor, our
data demonstrate that RINT1 functions as an oncogene
in GBM. Furthermore, the absence of somatic mutations
or gene fusions involving RINT1 validates our approach
of identifying candidate oncogenes based just on copy
number alterations and consequent mRNA expression
changes. Delineating the mechanisms and pathways
through which RINT1 promotes GBM tumorigenesis
will be necessary as a next step to identify new points
of therapeutic intervention for this devastating disease.
Supplementary Material
Supplementary material is available at Neuro-Oncology
Journal online (http://neuro-oncology.oxfordjournals.
org/).
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